-
公开(公告)号：US20230210909A1
公开(公告)日：2023-07-06
申请号：US17998199
申请日：2021-05-10
申请人： Celularity Inc.
发明人： Robert J. HARIRI , Xiaokui ZHANG , Shuyang HE , Kathy KARASIEWICZ-MENDEZ , Qian YE , Tanel MAHLAKOIV , Stacy HERB , Corey CASPER
摘要： Provided herein are methods of using CD10+, CD34−, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of SARS-CoV-2 related acute respiratory failure and ARDS (COVID-19).
-
公开(公告)号：US20220160787A1
公开(公告)日：2022-05-26
申请号：US17439671
申请日：2020-03-16
申请人： Celularity Inc.
发明人： QIAN YE , Joseph GLEASON , Lin KANG , Robert J. HARIRI , Shuyang HE , Xiaokui ZHANG , Valentina ROUSSEVA
IPC分类号： A61K35/50
摘要： The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.
-
公开(公告)号：US20220118014A1
公开(公告)日：2022-04-21
申请号：US17309451
申请日：2019-12-02
申请人： Celularity Inc.
IPC分类号： A61K35/17 , A61P35/02 , C07K14/725 , C12N15/86 , C12N5/073 , C12N5/0783
摘要： The present invention discloses populations of T cells expressing a chimeric antigen receptor (CAR), wherein said T cells are placental T cells derived from cord blood, placental perfusate, or a mixture thereof. Such populations of cells are shown to be improved in a number of aspects over alternative populations of cells such as those derived from peripheral blood mononuclear cell T cells. It also discloses methods of treating cancer, such as a hematologic cancer, e.g., a B cell cancer, or a symptom thereof in a patient in need thereof. These methods comprise administering to the patient an amount of the population of T cells of any one of the invention effective to alleviate the cancer or symptom thereof in the patient.
-
公开(公告)号：US20190307686A1
公开(公告)日：2019-10-10
申请号：US16194278
申请日：2018-11-16
申请人： Celularity, Inc.
发明人： Qian Ye
IPC分类号： A61K9/127 , C12N5/0783 , C12N5/073 , C12N5/0781 , C12N5/0789 , A61K35/17 , A61P35/00 , A61K35/50 , A61K35/22 , A61K31/7105 , A61K38/17 , A61K9/00
摘要： Several approaches to produce, isolate, and characterize exosomes recovered from a cultivated placenta or a portion thereof are provided. The alternatives described herein facilitate the production, isolation, and characterization of exosomes, which can be used as biotechnological tools and therapeutics. Also provided herein are populations of exosomes derived from placenta organ culture or culture of portions of the placenta. Also provided are compositions comprising the populations of exosomes and methods of their use for the treatment of subjects.
-
5.发明申请公开(公告)号：US20190093081A1
公开(公告)日：2019-03-28
申请号：US16147525
申请日：2018-09-28
申请人： CELULARITY, INC.
发明人： Lin KANG , Xiaokui ZHANG , William VAN DER TOUW , Robert J. HARIRI , Shuyang HE
IPC分类号： C12N5/0783 , A61P35/00 , A61K35/17 , C12N5/071
摘要： Provided provided herein are methods of treating a subject having a brain tumor, e.g., a glioblastoma by administering to the subject an effective amount of a cell population comprising human placenta-derived natural killer cells. Also provided are methods of suppressing the growth of brain tumor cells comprising contacting the glioblastoma cells with an effective amount of a cell population comprising human placenta-derived natural killer cells. Further provided are compositions comprising subject an effective amount of a cell population comprising human placenta-derived natural killer cells for use in the treatment of a brain tumor in a subject or for use in the manufacture of a medicament for treatment of a brain tumor in a subject.
-
公开(公告)号：US20190089124A1
公开(公告)日：2019-03-21
申请号：US15920717
申请日：2018-03-14
申请人： CELULARITY, INC.
发明人： Mohit B. Bhatia , Chris Lugo , Qian Ye , James W. Edinger
摘要： The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
-
公开(公告)号：US20180233218A1
公开(公告)日：2018-08-16
申请号：US15955636
申请日：2018-04-17
申请人： CELULARITY, INC.
摘要： Methods, computer systems, and computer program products for maintaining a stem cell registry comprising information about a plurality of stem cell units. A donor is enrolled in the stem cell registry. A stem cell unit from the donor is characterized. Information about the stem cell unit, obtained by the characterizing, is recorded in the stem cell registry. Computer readable media comprising a plurality of data records. One or more respective data records in the plurality of data records comprises (i) a collection identifier number that uniquely corresponds to a stem cell donation, (ii) a cord blood cell count associated with the stem cell donation, and (iii) a placenta blood cell count associated with the stem cell donation. Additional computer readable media comprising a plurality of data records. One or more respective data records in the plurality of data records comprises (i) a cord blood cell count associated with a stem cell donation, (ii) a placenta blood cell count associated with the stem cell donation, and (iii) an indication of at least two stem cell transplant units in the stem cell donation.
-
公开(公告)号：US09974840B2
公开(公告)日：2018-05-22
申请号：US14024081
申请日：2013-09-11
申请人： Celularity, Inc.
发明人： Mohit Bhatia , Chris Lugo , Qian Ye , James W. Edinger
CPC分类号： A61K38/39 , A61K8/65 , A61K2800/92 , A61Q19/00 , A61Q19/08 , C07K1/02 , C07K1/34 , C07K14/78 , A61K2300/00
摘要： The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.
-
公开(公告)号：US20230142803A1
公开(公告)日：2023-05-11
申请号：US18056088
申请日：2022-11-16
申请人： Celularity Inc.
发明人： Xiaokui ZHANG , Ivana DJURETIC , Lin KANG , Vanessa VOSKINARIAN-BERSE , Bhavani STOUT , Robert J. HARIRI , Wolfgang HOFGARTNER , James EDINGER , Eric LAW , Vladimer JANKOVIC
IPC分类号： C12N5/0783 , A61K35/17 , C12N5/078
CPC分类号： C12N5/0646 , A61K35/17 , C12N5/0634 , C12N2501/91 , C12N2501/145 , C12N2501/21 , C12N2501/26 , C12N2501/125 , C12N2501/22 , C12N2501/2302 , C12N2501/2306 , C12N2501/2307 , C12N2501/2315 , C12N2501/30 , C12N2501/999 , C12N2506/03
摘要： Provided herein are methods of producing natural killer (NK) cells and/or ILC3 cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and/or ILC3 cells and the NK cell and/or ILC3 cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.
-
公开(公告)号：US20230081199A1
公开(公告)日：2023-03-16
申请号：US18048291
申请日：2022-10-20
申请人： Celularity Inc.
IPC分类号： C12N5/073 , C12N15/11 , C12N15/113 , A61K35/50
摘要： Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.03 秒)
